Thymidilate synthase gene copy number as predictive marker of capecitabine efficacy in patients with breast cancer
| Autor: | Brian Leyland-Jones, R. Duchnowska, Kirsten Vang Nielsen, Krzysztof Adamowicz, M. Jaworska, Ann D. Thor, M Kulma-Kreft, Maria Litwiniuk, Kathy D. Miller, Małgorzata Foszczyńska-Kłoda, G. W. Sledge, Jacek Jassem, Robert Audet, Wojciech Rogowski, K. Zabkowska, S Debska, Jenny C. Chang, Changyu Shen, J Zok, Susan M. Edgerton |
|---|---|
| Rok vydání: | 2011 |
| Předmět: | |
| Zdroj: | Journal of Clinical Oncology. 29:10629-10629 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2011.29.15_suppl.10629 |
| Popis: | 10629 Background: Expression of key enzymes of the thymidylate synthase pathway may affect the efficacy of 5-FU and the pro-drug capecitabine (C). The gene copy number of thymidylate synthase (TS), thymidine phosphorylase (TP), and dihydrofolate reductase (DHFR) (high vs low defined by the median for each) was assessed and correlated with time-to progression (TTP) and progression-free survival (PFS). Methods: Adult female patients with pathologically confirmed breast cancer and locally advanced or metastatic disease were treated with C 1000 mg/m2 BID days 1-14 of a 21-day cycle. Human epidermal growth factor receptor 2 (HER2) and estrogen receptor (ER) expression was assessed immunohistochemically. Custom made TS, TP and DHFR FISH probes (Dako, Glostrup, Denmark) along with centromeric reference probes were used to evaluate gene copy number and gene to reference ratios in at least 60 morphologically intact non-overlapping nuclei. Markers dichotomized as high/low by the median were correlated with TTP and ... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|